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Abstract
Background:
Nearly 20% of adult Americans used herbal therapies in 2007, but greater than two-thirds failed
to report such use to their medical provider. Significant patient harm may occur when herbal
supplements are taken in conjunction with warfarin; however, patients and medical providers
may not be aware of these interactions and this may place patients at risk for life-threatening
bleeds or thrombotic complications.
Methods:
The authors determined the top 25 herbal and 25 nonherbal supplements used by Americans
using sales data from 2008, and each product was reviewed for its potential to interact with
warfarin. Electronic searches were conducted using the Natural Medicines Comprehensive
Database, AltMedDex (Micromedex) and Natural Standards databases. Search terms included
common herbal names, warfarin, and anticoagulants. Databases were reviewed for herb-drug
interactions with warfarin. Supplements with a purported theoretical interaction only were
excluded from the analysis.
Results:
Of the most commonly used herbal and nonherbal supplements used, more than half demonstrate
a clinically significant drug interaction with warfarin therapy. Specifically, 8 of 13 were found
to potentiate a bleeding risk, and 5 of 13 were found to decrease the effectiveness of warfarin.
Documented bleeding events have been linked to the use of some of these products (e.g.
cranberry, garlic, ginkgo, and saw palmetto); whereas others have been found to demonstrate a
clinically significant increase (e.g. glucosamine / chondroitin, essential fatty acids, multi-herb
products, evening primrose oil) or decrease (e.g. coenzyme Q10, soy, melatonin, ginseng, St.
John’s wort) in prothrombin time and required warfarin dose adjustments or vitamin K
administration.
Conclusions:
Of the most commonly used herbal and nonherbal supplements, the majority impacted
prothrombin times and 26% significantly impacted warfarin therapy safety or efficacy. The
combined use of herbal-warfarin products has the potential to result in significant bleeding or
thrombotic sequelae complicating the management of an already high-risk medication. Medical
providers must be proactive in asking about supplement use and then discussing the risks of
herbal-warfarin interactions with their patients.
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Review of Literature
Warfarin
Warfarin sodium, commonly known under the brand name Coumadin, is a popular
anticoagulant drug. It is the most widely prescribed oral anticoagulant in North America and has
been proven effective in the prevention of thromboembolic events in patients with chronic atrial
fibrillation, prosthetic heart valves, venous thromboembolism, and coronary artery disease (1).
Coumarins or vitamin K antagonists (VKAs) have been the foundation of oral anticoagulant
therapy for more than 50 years (2).
Atrial Fibrillation
Atrial fibrillation (AF) is a cardiac arrhythmia affecting an estimated in 2.2 million
people in America and 4.5 million in the European Union (3). In some cases, AF can cause chest
pain or heart failure, especially when the heart rhythm is very rapid (4). Frequently, people who
have AF are asymptomatic. However, even if asymptomatic, AF can increase the risk of stroke
(4). About 15 percent of patients with AF have experienced a stroke (5).
Clinical risk factors for AF include advanced age, diabetes, hypertension, congestive
heart failure, rheumatic and nonrheumatic valve disease, and myocardial infarction (6). Three
to five percent of people older than 65 years have atrial fibrillation (5). To reduce stroke risk in
patients with AF, anticoagulant and antiplatelet medications are used to thin the blood reducing
risk for emboli (5). Warfarin is the anticoagulant most frequently used for this purpose, and
aspirin is the antiplatelet drug most often used (5). Long-term use of warfarin in patients with
AF and other stroke risk factors can reduce stroke by 68 percent (5).
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Use of HDS in the US
In 1994, the Dietary Supplement Health & Education Act (DSHEA) was passed that
defines a supplement as: a product other than tobacco, is intended to supplement the diet,
contains one or more dietary ingredients, intended to be taken by mouth, and labeled as being a
dietary supplement (7). In 2004, dietary supplement sales exceeded $20 billion (8). According
to the National Center for Complementary and Alternative Medicine (NCCAM), “a national
survey conducted in 2007 found that 17.7 percent of American adults had used "natural
products" (i.e., dietary supplements other than vitamins and minerals) in the past 12 months (9).
The most popular products used by adults for health reasons in the past 30 days were fish
oil/omega 3/DHA (37.4%), glucosamine (19.9%), echinacea (19.8%), flaxseed oil or pills
(15.9%), and ginseng (14.1%)” as seen in figure 1 (10).

Figure 1: Frequencies and age-adjusted percentages of adults ≥18 yrs old who used nonvitamin, nonmineral,
natural products for health reasons in the past 30 days.
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Use of VKAs
In clinical practice, the use of VKAs is complicated. First, they have a limited
therapeutic window. Second, they exhibit substantial variability in dose response among
subjects. Third, they are susceptible to interactions with drugs and diet. Fourth, they have
laboratory control that can be difficult to standardize. Lastly, there are difficulties in dosing as a
consequence of patient nonadherence and miscommunication between the physician and patient
(2). Warfarin use is somewhat restricted by a justifiable fear of bleeding as well as drug and food
interactions that are frequently cited as causes of adverse events with warfarin. Noting this
challenging situation in the utilization of warfarin, safety must be carefully practiced while
taking it.
Mechanism of Warfarin
The effects of warfarin occur due to interference with the cyclic interconversion of
vitamin K and its 2,3 epoxide (vitamin K epoxide). Vitamin K is a cofactor for the carboxylation
of glutamate residues to -carboxyglutamates (Gla) on the N-terminal regions of vitamin Kdependent proteins (11). These proteins include coagulation factors II, VII, IX, and X, and
require vitamin K for -carboxylation for biological activity. By inhibiting the vitamin K
conversion cycle, warfarin stimulates hepatic production of partially decarboxylated proteins
with decreased coagulant activity (11).
Carboxylation supports binding of the vitamin K-dependent coagulation factors to
phospholipid surfaces, thus increasing blood coagulation (11). In order for -carboxylation to
work effectively, the reduced form of vitamin K (vitamin KH2) is required. Coumarins block the
formation of vitamin KH2 by inhibiting the enzyme vitamin K epoxide reductase, thereby
restricting the -carboxylation of the vitamin K-dependent coagulant proteins (11). The vitamin
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K antagonists also inhibit carboxylation of the regulatory anticoagulant proteins C and S. Low
doses of vitamin K1 (phytonadione) are capable of aiding in overcoming the anticoagulant effect
of coumarins because vitamin K1 bypasses vitamin K epoxide reductase (11). Subjects treated
with large doses of vitamin K1 (usually greater than five mg) can be unaffected by warfarin for
up to a week because vitamin K1 accumulating in the liver is available to bypass vitamin K
epoxide reductase (11). Figure 2 depicts warfarin interaction in the vitamin K cycle (12).

Figure 2: Warfarin Interaction in the Vitamin K Cycle

Factors Influencing Warfarin’s Effects
The anticoagulant response to warfarin is affected by pharmacokinetic factors, including
drug and herbal/nonherbal supplement interactions that affect its absorption or metabolic
clearance, genetic factors such as hereditary resistance to warfarin, and food interactions such as
dietary vitamin K intake (11). Warfarin requires monitoring and frequent dose adjustment to
maintain the desired therapeutic action and minimize adverse bleeding events. A thrombosis is a
result of underanticoagulation, which can be fatal. A hemorrhage is a result of overanticoagulation, which can also be life-threatening. Length of treatment varies, from 6 weeks to
9

6 months for venous thrombosis, to life-long treatment for cardiac indications or repeated
thrombosis (13).
Patients taking oral anticoagulant drugs, such as warfarin, must regulate their
international normalized ratio (INR) measured routinely with appropriate anticoagulant dose
adjustment. Some patients are particularly sensitive to oral anticoagulants and, in such
individuals, small increases in dose, or introduction or discontinuation of interacting medicines,
herbal preparations and certain foods can cause significant changes in the anticoagulant effect
(13). Polypharmacy is not uncommon, which complicates the efficacy of warfarin. Patients
taking warfarin should be aware of the risks of taking other prescribed or purchased medicines,
herbal products and specific foods without first discussing it with their physician.
Dietary Interactions with Warfarin
As previously stated, warfarin use is subject to dangerous interactions with other
medications as well as some food products. Due to the actions of warfarin interfering with the
vitamin K conversion cycle, dietary vitamin K intake must remain consistent on a daily basis to
reduce the risk of hemorrhage or thrombosis. Persons on long-term warfarin therapy are
vulnerable to fluctuating levels of dietary vitamin K, which is obtained predominantly from
phylloquinones found in plant foods (11).
Phylloquinones inhibit the anticoagulant effect of warfarin because they are reduced to
vitamin KH2 through the warfarin-insensitive pathway (11). Significant fluctuations in vitamin K
intake occur in both healthy and sick individuals. Increased intake of dietary vitamin K sufficient
to lessen the anticoagulant effect of warfarin occurs in patients consuming green vegetables or
vitamin K-containing supplements while following weight-reduction diets as well as in patients
supplementing with intravenous vitamin K (11). Reduced dietary vitamin K intake has the
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potential to affect warfarin efficacy in sick patients treated with antibiotics and intravenous fluids
without vitamin K supplementation and in circumstances of fat malabsorption (11).
Medicinal Interactions with Warfarin
Warfarin also interacts with some common drugs such as aspirin, nonsteroidal
antiinflammatory drugs (NSAIDs), and penicillins in high doses (11). These drugs inhibit
platelet function and thus increase the risk of warfarin-associated bleeding. Of these, aspirin is
the most critical because of its universal use and drawn out effect. Aspirin and nonsteroidal
antiinflammatory drugs can also increase the risk of upper gastrointestinal bleeding as a result of
them producing gastric erosions (11). The risk of clinically significant bleeding is amplified
when elevated amounts of aspirin are taken throughout high-intensity warfarin therapy (11).
Herbal and Nonherbal Dietary Supplement Interactions with Warfarin
Warfarin has been documented to interact with herbal and nonherbal dietary supplements
(HDS) (11). However, little is known about the great extent to which some of the most
commonly used HDS may impact warfarin safety and efficacy. Although herbal remedies are
perceived as being natural and therefore safe, many have adverse effects that can sometimes
produce life-threatening consequences.
It is important to determine the degree to which HDS can interfere with warfarin because
of the rapidly growing dietary supplement market and consumer demand in the United States.
According to the research completed through this thesis, the top five products in Figure 1 (fish
oil, flaxseed oil, glucosamine, echinacea, and ginseng) were shown to have an interaction with
warfarin. Also, as documented in the manuscript portion of this thesis, garlic (37-45), ginkgo
(49, 52-56) and St. John’s wort (80-84) should be avoided while taking warfarin. Because of the
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high risk of adverse effects while concurrently taking these common HDS and warfarin, a brief
review of each HDS will follow.
Fish Oil and Flaxseed Oil
Fish oil and flaxseed oil both had minor interactions, mainly with platelets (35-36).
Many people consume fish and flax seed oils because of the purported health benefits of the
omega-3 fatty acids they contain. Omega-3 fatty acids have been thought to reduce the risk for
cardiovascular disease and some cancers, as well as improve brain health. Some research has
shown that the omega-3 component of fish oils may suppress thromboxane A2 synthesis. This
may intensify the effects of warfarin, thus increasing the chances of bleeding. Conflicting
research has suggested that fish oil does not have an additive effect with aspirin. Data does
suggest that 3-6g/day does not affect INR (35-36).
Ginseng
The source of the ginseng root and its method of extraction can result in a wide array of
ginseng products. Ginseng is touted as an immune system stimulant that increases vigor, sexual
potency, and longevity, and for use as an antidiabetes agent (14). It is also used as medicine in
Chinese culture for congestive heart failure (CHF), myocardial infarction, and angina pectoris
(14). Ginseng use should be avoided while taking warfarin (76-78). Ginseng may inhibit
platelet aggregation consequently decreasing the effects of warfarin. A recent study inspecting
the effect of 3 weeks of American ginseng on the effect of warfarin in healthy volunteers found a
statistically significant but quantitatively small decrease in INR of 0.19, as well as a decrease in
warfarin plasma area under the curve (AUC) (15). These results imply that this specific ginseng
preparation may produce a minor reduction in the efficacy of warfarin, perhaps by way of
accelerated clearance.
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Glucosamine
Glucosamine is recommended to be used with caution while taking warfarin although the
exact mechanism of the interaction is unknown (2-4). Glucosamine is a chemical component of
heparin, a widely used injectable anticoagulant (16). It is possible that the combining of warfarin
with higher-dose glucosamine and chondroitin might have had an additive pharmacodynamic
effect on coagulation (16). At the usual dosages of glucosamine (1500 mg) and chondroitin
(1200 mg) used on a daily basis, these supplements alone or in combination do not appear to
cause a clinically significant interaction with warfarin (16). Nevertheless, it is advised to
monitor for INR changes in patients taking warfarin and beginning a supplement or drug that has
not been thoroughly investigated for its effect on warfarin.
Echinacea
Echinacea is commonly thought to stimulate the immune system and therefore prevent
infections. It has been shown to have minor interactions with warfarin. Flavonoids from
echinacea may inhibit or induce cytochrome P450 enzymes, depending on their structure and
assay conditions (14). A minor impact of CYP function was established through in vivo
assessment of botanical supplementation on human cytochrome P450 phenotypes: citrus
aurantium, echincea purpurea, milk thistle, and saw palmetto.
Garlic
Garlic is often used by patients for remedy of infectious conditions because of its
presumed antimicrobial and immune-boosting activity. Garlic has been considered to have
cholesterol-lowering and other antiatherosclerotic and antihypertensive properties and is used in
the prevention of cardiovascular disease (14). It has been shown to increase fibrinolytic activity,
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and may inhibit platelet aggregation by reducing thromboxane B2 thereby, increasing risk for
bleeding.
Garlic’s active component, ajoene inhibits collagen-induced platelet aggregation; thus,
patients with cardiovascular disease often use garlic for its antiplatelet and fibrinolytic effects
(14). Nevertheless, the risk of bleeding in patients using warfarin increases, so its concomitant
use should be avoided. It is worthy to note that not all garlic products contain the constituents
that possess “antiplatelet properties”. It has been advised that garlic supplements be
discontinued ten days prior to surgery to prevent excessive bleeding. Ingestion of normal
amounts of dietary garlic should not affect bleeding times (37-45).
Ginkgo
Ginkgo is a popular HDS and is one of the bestselling herbal remedies in the United
States for cognitive impairment (14). Ginkgo biloba beginnings date back centuries to the
Permian period, making it one of the world’s oldest living tree species (14). The main
implications for ginkgo use are peripheral vascular disease such as intermittent claudication and,
more chiefly, "cerebral insufficiency" (17). It has been documented to increase the risk of
bleeding while taking warfarin. This is thought probable by inhibition of cytochrome P450 2C9
by ginkgo. Also, ginkgo is thought to displace platelet activating factor (PAF), inhibiting PAFinduced platelet aggregation.
St. John’s Wort
St. John’s wort is frequently used to treat depression, anxiety, sleep disorders, the
common cold, herpes, and the human immunodeficiency virus (HIV) (14). It acts as a hepatic
cytochrome P450 enzyme inducer (CYP2C9, CYP1A, CYP3A4). Simultaneous use of St.
John’s wort with warfarin reduces prothrombin time, which may produce subtherapeutic
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anticoagulation and increase the risk of thromboembolism (14). Patients with a history of stroke,
thrombosis, atrial fibrillation, or prosthetic cardiac valves should avoid the use of St. John’s wort
while taking warfarin (14).
Conclusion
From this evidence alone, there are major risks when using HDS and warfarin
concomitantly. Steps must be taken to bridge the communication gap that exists between
physicians and patients with regard to supplement use. To ensure that patients are taking
warfarin safely, physicians must be aware of the risks HDS pose with concomitant use of
warfarin. Physicians must be proactive in asking their patients about such use and discussing the
risks involved to aid in preventing serious complications with an already high risk medication.
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Introduction:
For centuries, botanicals and their derivatives have been utilized for prevention and
treatment of disease. Indeed, even today, due to extensive availability and widespread
acceptance, herbal and dietary supplement (HDS) use has become commonplace. One out of
five American’s reports using at least one HDS in the last twelve months, a trend that has
continued to gain momentum over the last decade (1). Growing concern for patient safety has
driven international and national groups in efforts towards regulation of the herbal supplement
industry, but with limited success. In the present day era of patient guided research, selection
and self-treatment with supplements, it is imperative that medical providers be proactive in
inquiry about HDS use and provide relevant guidance in efforts to minimize potential adverse
events. When combined with prescription drugs, herbal-drug interactions are of great concern
because they may lead to unexpected, serious patient harm.
The supplement industry is the fastest growing share of the US pharmaceutical industry,
with annual earnings approaching 24 billion dollars in 2007 (2). Today, greater than 1500
products claiming “functional support” of the bodies various organ systems line the shelves of
pharmacies and health food stores, easily accessible to an often uneducated consumer.
Ironically, HDS are not considered “drugs” by the Food and Drug Administration (FDA), and are
therefore free from the safety and regulatory standards set in place by the FDA for other over the
counter and prescription products. In 1994, the Dietary Supplement Health and Education Act
(DSHEA) was passed and outlines the US regulations set in place for herbal and nonherbal
supplements: the manufacturer is to ensure that the product is safe and labeling must include
product ingredients (3). As a food source the preparation, packing, and holding of HDS are
governed by the FDA’s ‘Good Manufacturing Practices’ (4). In June of 2007, the FDA
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established regulations to require current ‘Good Manufacturing Practices” for dietary
supplements that require dietary supplement manufacturers to evaluate the identity, purity,
strength, and composition of their dietary supplements (5). Although these measures may help,
the quandary with HDS continues to be, that the pharmacologic effects of these products are
undefined, unpredictable, and potentially unsafe, yet the well-intended consumer has little
knowledge of this. This can present the greatest risk to patients with multiple medical comorbidities, fragile end organ function, and those on complicated drug regimens. In 2002, the
World Health Organization launched a global strategy with end goals of promoting consumer
safety through industry regulation and standardization (6). Clearly, the unregulated use of HDS
is not just a national, but an international concern.
The introduction of warfarin sodium in 1954 revolutionized the prophylaxis and
treatment of thromboembolic disorders, and remains the gold standard oral anticoagulant. More
than 22 million prescriptions for warfarin were filled in 2008, and enormous health care
resources are dedicated to its management. In spite of efforts to achieve tight control of the
international normalized ratio (INR), warfarin accounts for more emergency room visits than any
other drug excluding insulin. In 2009, the Joint Commission of Healthcare Accreditation made
the appropriate use of warfarin a National Patient Safety Goal (7). As part of this effort, it is
crucial to understand the influence that HDS use may have on INR variability when taken
concomitantly with warfarin. Such an understanding must be constantly reappraised as the kinds
of HDS used varies as well as their relative frequency and quantify of use.
Methods:
The authors determined the top 20 herbal and 20 nonherbal supplements used by
Americans using sales data from 2008 and each product was reviewed for its potential to interact
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with warfarin (8). Electronic searches were conducted using the Natural Medicines
Comprehensive Database, AltMedDex (Micromedex) and Natural Standard databases. Search
terms included common herbal names, warfarin, and anticoagulants, and drug-drug interactions.
Databases were reviewed for herb-drug interactions with warfarin. Databases were searched for
relevant case reports and any clinical trials which documented an herbal/supplement – drug
interaction with reported changes in INR, bleed risks, or thromboembolic events. Collected data
was limited to English only reports and those with a documented human interaction.
Supplements with a purported theoretical interaction only were excluded from the analysis.
Results:
Of the 40 most commonly used herbal and nonherbal supplements, more than half
demonstrate an indirect or direct drug interaction with warfarin therapy. Of the top 10 most
commonly used supplements, 80% have been reported to interact with warfarin therapy. Overall,
14 of 40 were associated with a clinically significant change in INR. Specifically, 9 of 14 were
found to potentiate a bleeding risk, and 5 of 14 were found to decrease the effectiveness of
warfarin. Documented bleeding events have been linked to the use of some of these products
(e.g. cranberry, garlic, ginkgo, and saw palmetto); whereas others have been found to
demonstrate a clinically significant increase (e.g. glucosamine / chondroitin, essential fatty acids,
multi-herb products, evening primrose oil) or decrease (e.g. coenzyme Q10, soy, melatonin,
ginseng, St. Johns’s wort) in prothrombin time thus necessitate warfarin dose adjustments or
vitamin K administration.
Discussion:
The HDS industry has experienced enormous growth with extensive consumer acceptance
and trust. A survey of 100 patients with CV disease on warfarin showed that many patients do
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not view HDS as drugs, and most do not consult with their pharmacist/physician before taking a
HDS (9). More than 2/3 of patients who use HDS fail to communicate use to their
physicians/pharmacists, and physicians often fail to ask patients about HDS consumption as well
(5, 9). The reasons for the communication gap are many: patients believe that health care
professionals lack knowledge of or acceptance for HDS, patients perceive HDS as "natural" and
do not relate their use to drug interaction (9), and medical providers may fail to ask about HDS
use due to a lack of knowledge, confidence, or comfort with the subject matter (10). Addressing
these issues will be paramount as clinicians seek to bridge this gap in order to improve safety
outcomes, particularly in high-risk patient groups.
A survey of the literature shows that anticoagulant/antiplatelet therapies are among the
drug classes most likely to interact with HDS (11). Of the 40 most commonly used HDS, more
than half demonstrated a clinically significant change in INR values, and the majority were
associated with a bleeding event or thromboembolic complication. While most of these reports
are cited as individual case reports, the true level (degree/risk) of harm for warfarin-treated
patients may actually be greater than is documented. Pharmacokinetic properties and toxicity
parameters of individual herbs are not well studied, and drug-drug, drug-disease interactions are
largely unknown. Additionally, a vast number of supplements are not marketed as “single-entity”
products, but rather a potpourri of dozens or hundreds of individual ingredients. The new FDA
regulation should impact quality of supplements. Unfortunately, companies have to be
compliant to the new regulation by supplement June 2008, 2009, or 2010, depending on the
number of personnel employed at the company. This will continue to impact the consistency of
HDS in the marketplace. Without prior study it is completely unclear if the enhanced quality
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which may provide relatively higher or lower HDS concentrations with favorability or
unfavorability impact the many drug-HDS interactions.
Development, implementation, and adherence to a comprehensive management program
that outlines standards of care have been shown to improve safety outcomes in anticoagulated
patients. As such, inquiry and recommendation about herbal supplement use is an essential part
of such a program. Important aspects to incorporate may be the following: proactive inquiry
about herbal or supplement use separately from prescription or over the counter drug use;
documentation of use in the medical record; active education of known risks/interactions
between the specified herbal product and warfarin; and more frequent INR monitoring if
necessary. Other valuable education points for patients who use HDS may be: encourage
dialogue before use with physician/pharmacist; take the product consistently to achieve a more
predictable effect on INR; to purchase the same brand of product to minimize constituent
variability; follow up with routine testing as instructed; bring the HDS with them to all scheduled
appointments; report any adverse events to their medical provider immediately. Additionally,
encourage selection of supplements that are verified by the United States Pharmacopeia (USP).
Likewise, physicians and other medical providers must acknowledge a “communication
gap” exists with their patients and make efforts to minimize this barrier. Self-education is
critical, so that a knowledgeable exchange about the supplement industry, including DHSEA and
rationale for safety risks, can be undertaken with patients. Physicians must recognize that HDS
use is common and underreported, and therefore must be proactive and specific in patient
interview. It is essential to be forthright with regard to the risks/benefits of using supplements,
so that the patient can make an informed and educated decision. Likewise, it is imperative that
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the physician be familiar with on-line herbal databases, such as AltMedDex (Micromedex), and
utilizes them to search for herbal information, such as herbal-warfarin interactions.
Steps must be taken to bridge the communication gap that exists between physicians and
patients with regard to supplement use. While warfarin remains the gold standard anticoagulant
drug therapy for long-term management of patients at risk for thromboembolism, its safe use can
be compromised by many factors, including HDS consumption. Our data shows that of the most
commonly used HDS, warfarin-related drug interactions are very common and have been
associated with bleeding. This risk is greatest in the 10 most commonly used herbal
supplements, where 8 of 10 have demonstrated an HDS-warfarin interaction. Our research
highlights/emphasizes the widespread risk that warfarin-treated patients are exposed to when
self-medicating with HDS. It is imperative that action be taken to address communicationrelated barriers with regard to HDS use, and should include the steps outlined above. As
hospitals seek to achieve compliance with the Joint Commission’s 2009 National Patient Safety
Goals of medication reconciliation and appropriate anticoagulant management, this creates a
perfect opportunity/forum for HDS-focused education. Future research should be aimed at
“bridging the gap” through the development and implementation of both physician-focused and
patient-focused educational tools.
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Warfarin/HDS Interaction Table
Supplement

Recommendation Warfarin
Platelet
for Management Interaction Interaction
CAM therapies that may increase the risk of bleeding
Chondroitin
+
!
sulfate (2-4)

Cod liver oilEssential Fatty
Acids (5-9)

Q

Cranberry (1022)

!

Evening
primrose oil (31)

!

+

Fish oilEssential Fatty
Acids (35,36)

Q

+

Garlic (37-45)

∅

+

+

Mechanism
Chondroitin is a small
component of a
heparinoid and might
have weak anticoagulant
activity
Cod liver oil contains
omega-3 fatty acids,
which may interfere
with the ?????
Unknown mechanism:
One proposed
mechanism is that
flavanoids in cranberry
may interfere with the
P450 2C9 metabolism of
warfarin, thus
prolonging its effects.
Another hypothesis is
that cranberry may
increase the sensitivity
of clotting factors to the
effects of warfarin
Primrose oil contains
gamma-linolenic acid
which has been show to
inhibit thromboxane B2
production and increase
prostacyclin production
Some research shows
that the omega-3
component of fish oil
may suppress
thromboxane A2
synthesis. Conflicting
research suggests that
fish oil does not have an
additive effect with
aspirin
Garlic has been shown
to increase fibrinolytic

Patient Information

-Avoid drinking in large
quantities
-Have INR checked more
frequently with chronic
consumption

Data does suggest that 3-6g/day
does not affect INR

-Not all garlic products contain
the constituents that possess
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Supplement

Recommendation
for Management

Ginger (34,4651)

Q

Ginkgo biloba
(49, 52-56)

∅

Glucosamine (24)

!

Melatonin (62)

!

Saw palmetto
(63, 64)

!

Warfarin
Interaction

Platelet
Interaction

+

+

+

+

Mechanism

Patient Information

activity, and may inhibit
platelet aggregation by
reducing thromboxane
B2

“antiplatelet properties”
-Garlic supplements should be
stopped 10 days prior to surgery
-Ingestion of normal amounts of
dietary garlic should not affect
bleeding times
-Caution with intake exceeding
4 grams of dried or 15 grams of
raw ginger daily

Mixed results in studies:
one suggests a
significant inhibition of
platelet aggregation,
where two others
showed no affect on
platelet function
Probable cytochrome
P450 2C9 inhibition by
ginkgo. Also, ginkgo is
thought to displace
platelet activating factor
(PAF), inhibiting PAFinduced platelet
aggregation
May have antiplatelet
activity
Unknown mechanism

+

Saw palmetto may
inhibiti cyclooxygenase,
leading to increased risk
of bleed

CAM therapies
that may
decrease the
effects of
warfarin
Coenzyme Q10 (72-74)

Ginseng
(American)
(76-78)

∅

+

May inhibit platelet
aggregation

Ginseng

∅

+

May inhibit platelet
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Supplement

Recommendation
for Management

Warfarin
Interaction

(Panax) (76-78)
Q
Soy (79)

+

∅

+

St. John’s wort
(80-84)

Platelet
Interaction

Mechanism

Patient Information

aggregation
Soy isoflavones may
alter warfarin drug
absorption, metabolism
or biliary excretion.
They may also have
antiplatelet effect
St. John’s wort is a
cytochrome P450
enzyme inducer
(CYP2C9, CYP1A2,
CYP3A4)
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